Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLC

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Related Keywords

Chul Kim ,Medstar Health ,Georgetown University Lombardi Comprehensive Cancer Center ,Georgetown Lombardi Comprehensive Cancer Center ,Onclive Tv ,Precision Medicine In Oncology ,Lung Cancer ,